Gan & Lee Pharmaceuticals.

This study tests an injection called GZR18 in 140 obese adults with moderate to severe obstructive sleep apnea who cannot or will not use a CPAP machine. The goal is to see if the drug improves breathing during sleep and helps with weight loss over 52 weeks. Participants will rec…

This early-stage study tests a new drug called GLR2037 in 65 men with metastatic prostate cancer that has spread to bones or soft tissues. The main goal is to check the drug's safety and how the body processes it. Participants must have had prior hormone therapy and still have ca…

This study tests a new insulin called GZR33 against an approved insulin (Tresiba) in 350 adults with type 2 diabetes whose blood sugar is not well controlled by pills alone. The main goal is to see if GZR33 works as well or better at lowering blood sugar over 26 weeks. Participan…

This study tests a new injectable medicine, GZR101-80, for people with type 2 diabetes that is not well controlled by current pills or basal insulin. About 345 adults will receive the drug for 16 weeks to see if it lowers blood sugar and HbA1c safely. The goal is better daily con…

This study tests an injectable drug called GZR18 in 140 obese adults with moderate-to-severe obstructive sleep apnea who already use a breathing machine (PAP). The goal is to see if the drug improves breathing during sleep, reduces symptoms, and helps with weight loss compared to…

This early-stage trial will test whether a new injection called GLR1044 works like the approved drug Dupixent in the body. About 198 healthy Chinese men will receive a single dose of either GLR1044 or Dupixent. Researchers will compare how the drugs are absorbed and processed, an…